Cover Image
市場調查報告書

高雪氏症:主要9個國家的市場預測

Gaucher's Disease Forecast in 9 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339844
出版日期 內容資訊 英文 40 pages
訂單完成後即時交付
價格
Back to Top
高雪氏症:主要9個國家的市場預測 Gaucher's Disease Forecast in 9 Major Markets 2015-2025
出版日期: 2015年08月01日 內容資訊: 英文 40 pages
簡介

高雪氏症 (GD) 是由於GBA遺傳基因的先天性常染色體隱性突變引起的疾病。GBA遺傳因子是與生產酶葡糖腦苷脂酶這個酵素有關的遺傳因子,缺乏這個酵素就會導致葡糖腦苷脂和其他類似的物質積蓄在巨噬細胞和單核細胞(白血球)並沉積在各種器官,包括脾,肝,腎和肺中。等到累積到毒性發作的水準就會帶給各個器官不良影響。

本報告提供全球主要9個國家(美國,法國,德國,義大利,西班牙,英國,巴西,日本,印度) 的高雪氏症發病情形相關分析,提供您疾病概要和目前的患病人數,性別·各年代 (以五歲為區分) 的詳細情況,各地區·各民族趨勢,風險要素,疾病診斷與預後,主要的症狀和併發症,未來性的趨勢預測 (今後10年份) 等資訊,為您概述為以下內容。

概要

簡介

疾病的原因

風險要素與預防法

疾病診斷

各地區/各民族的差異

疾病的預後與臨床經過

疾病相關的主要併發症/特徵

患者數的定量化技術

高雪氏症 (GD) 的最大患病人數

高雪氏症的主要症狀與特徵

  • 高雪氏症患者的表現型別明細
  • I型高雪氏症患者的遺傳基因型
  • III型高雪氏症患者的遺傳基因型
  • 高雪氏症的肌肉骨骼系統的併發症
  • 高雪氏症的血液學併發症

參考文獻

附錄

圖表一覽

目錄
Product Code: GAUD0010815

Gaucher's Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA gene. This gene is responsible for providing the instructions for the production of the enzyme glucocerebrosidase. Without this enzyme, glucocerebroside and other similar substances can accumulate in macrophages and monocytes (white blood cells) and are deposited in various organs, including the spleen, liver, kidneys and lungs. This build-up can reach toxic levels which results in organ and tissue damage. This report provides the current prevalent population for GD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GD include:

  • Splenomegally
  • Hepatomegally
  • Haematological conditions
  • Musculoskeletal conditions
  • Gall stones

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global GD's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of GD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on GD's prevalent population.
  • Examination of the prevalence of the different causative gene mutations for GD.
  • Identify sub-populations within GD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of GD patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors and Prevention

Diagnosis of the Disease

Variation by Geography /Ethnicity

Disease Prognosis and Clinical Course

Key Co-Morbid Conditions / Features Associated with the Disease

Methodology for Quantifications of Patient Number

Top Line Prevalence for Gaucher's Disease (GD)

Main Complications and Features of GD

  • Phenotypic Sub-type of GD Patients
  • Genotype of Type I GD Patients
  • Genotype of Type III GD Patients
  • Musculoskeletal Complications of GD
  • Haematological Involvement of GD

References

Appendix

List of Tables and Figures

  • Prevalence of GD, total (000s)
  • Prevalence of GD, males (000s)
  • Prevalence of GD, females (000s)
  • GD by Phenotypic sub-Type, total (000s)
  • Genotype of Type I GD Patients, total (000s)
  • Genotype of Type III GD Patients, total (000s)
  • Bone and Joint Pain in Patients with GD, total (000s)
  • Radiological Bone Disease in Patients with GD, total (000s)
  • Erlenmeyer Flask Deformity in Patients with Type I GD, total (000s)
  • Presence of Anaemia in Patients with GD, total (000s)
  • Presence of Thrombocytopenia in Patients with GD, total (000s)
  • Presence of Bleeding Tendencies in Patients with GD, total (000s)
  • USA Prevalence of GD by 5-yr age cohort, males (000s)
  • USA Prevalence of GD by 5-yr age cohort, females (000s)
  • France Prevalence of GD by 5-yr age cohort, males (000s)
  • France Prevalence of GD by 5-yr age cohort, females (000s)
  • Germany Prevalence of GD by 5-yr age cohort, males (000s)
  • Germany Prevalence of GD by 5-yr age cohort, females (000s)
  • Italy Prevalence of GD by 5-yr age cohort, males (000s)
  • Italy Prevalence of GD by 5-yr age cohort, females (000s)
  • Spain Prevalence of GD by 5-yr age cohort, males (000s)
  • Spain Prevalence of GD by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of GD by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of GD by 5-yr age cohort, females (000s)
  • Brazil Prevalence of GD by 5-yr age cohort, males (000s)
  • Brazil Prevalence of GD by 5-yr age cohort, females (000s)
  • Japan Prevalence of GD by 5-yr age cohort, males (000s)
  • Japan Prevalence of GD by 5-yr age cohort, females (000s)
  • India Prevalence of GD by 5-yr age cohort, males (000s)
  • India Prevalence of GD by 5-yr age cohort, females (000s)
Back to Top